Analytical Science, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
Analytical Science, Merck & Co., Inc., Rahway, New Jersey 07065, United States.
J Pharm Biomed Anal. 2020 Sep 5;188:113401. doi: 10.1016/j.jpba.2020.113401. Epub 2020 Jun 4.
Cleaning verification (CV) is a critical step in the pharmaceutical manufacturing process to eliminate or reduce unacceptable contamination of a product as a result of insufficiently cleaned equipment surfaces. The main concern is cross contamination with active pharmaceutical ingredients (APIs) from previous runs that may impact patient safety. Current conventional approaches involve rather tedious sample preparation and analytical methods with relative lengthy analysis time. Potent APIs possessing low acceptable daily intake (ADI) values require analytical methods for CV with very low detection limits to confirm that these APIs are below their acceptance limits prior to the next manufacturing process. In this work, a novel end to end CV workflow was developed, which includes the automated sample and calibration solution preparation as well as high throughput analysis by ultra-high-performance liquid chromatography (UHPLC) coupled with single quadrupole mass spectrometry in multiple injection chromatography and selected ion monitoring mode (MIC-MS-SIM). The method was validated using ten model compounds. Acceptable specificity, linearity (R > 0.997) and single digit ng/mL LOQ and LOD were achieved for all model compounds. This approach was also successfully applied to the analysis of 22 internal CV samples from an internal program.
清洁验证 (CV) 是制药生产过程中的一个关键步骤,旨在消除或减少因设备表面清洁不彻底而导致产品受到不可接受的污染。主要关注点是来自先前批次的活性药物成分 (API) 的交叉污染,这可能会影响患者安全。目前的常规方法涉及到相当繁琐的样品制备和分析方法,分析时间相对较长。具有低可接受日摄入量 (ADI) 值的有效 API 需要具有非常低检测限的 CV 分析方法,以确认在下一次生产工艺之前,这些 API 低于其可接受限度。在这项工作中,开发了一种新颖的端到端 CV 工作流程,其中包括自动化的样品和校准溶液制备以及通过超高效液相色谱 (UHPLC) 与多注入色谱和选择离子监测模式 (MIC-MS-SIM) 结合进行高通量分析。该方法使用十种模型化合物进行了验证。所有模型化合物均达到了可接受的特异性、线性 (R > 0.997) 以及单个数字 ng/mL 的 LOQ 和 LOD。该方法还成功地应用于内部计划中 22 个内部 CV 样品的分析。